Cybin Inc. (CYBN) — Cybin reported results for its fiscal first quarter ended June 30, 2025, with $118.7 million in cash bolstered by a recent $50 million convertible debenture financing.
The company highlighted European and UK MHRA approvals for EMBRACE, the second pivotal study of CYB003 (deuterated psilocin) as adjunctive treatment for major depressive disorder, spanning 330 participants across roughly 60 sites. Enrollment completion in the CYB004 (DMT) Phase 2 generalized anxiety disorder study was expected in August 2025.
Source: finance.yahoo.com
For the rest of that week's sector news, read our week in review.